Clinical Efficacy and Safety of a Short Regimen of Azithromycin Sequential Therapy vs Standard Cefuroxime Sequential Therapy in the Treatment of Community-Acquired Pneumonia: An International, Randomized, Open-Label Study

References

• Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275 (2): 134–141.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Guidelines for the manage-ment of adults with community-acquired pneumonia: Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163 (7): 1730–1754.
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Dowell SF, Mandell LA, File TM, Muster DM, Fine MJ. Practice guidelines for the management of com-munity-acquired pneumonia in adults. Clin Infect Dis 2000; 31 (2): 347–382.
   PubMed Web of Science ®Google Scholar
• Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C. Update of practice guidelines for the man-agement of community-acquired pneumonia in immunocom-petent adults. Clin Infect Dis 2003; 37 (11): 1405–1433.
   PubMed Web of Science ®Google Scholar
• Ramirez JA. Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis 1995; 22 (1-2): 219–223.
   PubMed Web of Science ®Google Scholar
• Cunha BA. Intravenous to oral switch therapy. Drugs Today 2001; 37 (5): 311–319.
   PubMed Web of Science ®Google Scholar
• Peters DH, Heather AF, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992; 44 (5): 750–799.
   PubMed Web of Science ®Google Scholar
• Schonwald S, Bari t B, Klinar I, Gunjata M. Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. Scand J Infect Dis 1994; 26 (6): 706–710.
   Google Scholar
• Rizzato R, Montemurro L, Fraioli P et al. Efficacy of a three-day course of azithromycin in moderately severe com-munity-acquired pneumonia. Eur Respir J 1995; 8 (3): 398–402.
   Google Scholar
• O'Doherty B, Muller O, Azithromycin Study Group. Randomized, multicenter study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Eur Clin Microbiol Infect Dis 1998; 17 (12): 828–833.
   PubMed Web of Science ®Google Scholar
• Schonwald S, Kuzman I, Ore§kovit K et al. Azithromycin: Single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome - A randomized study. Infection 1999; 27 (3): 198-202.
   Google Scholar
• Contopoulos-Ioannidis DG, Ioannidis JPA, Chew P, Lau J. Meta-analysis of randomized controlled trials on the com-parative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001; 48 (5): 691–703.
   PubMed Web of Science ®Google Scholar
• Kuzman I, Soldo I, Schonwald S, C'ulig J. Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: A retrospective study. Scand J Infect Dis 1995; 27 (5) :503-505.
   Google Scholar
• Plouffe J, Schwartz DB, Kolokathis A et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother 2000; 44 (7): 1796–1802.
   Google Scholar
• Vergis EN, Indorf A, File TM et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of com-munity-acquired pneumonia in hospitalized patients: A prospective, randomized, multicenter trial. Arch Intern Med 2000; 160 (9): 1294–1300.
   PubMedGoogle Scholar
• Paladino JA, Gudgel LD, Forrest A, Niederman MS. Cost-effectiveness of IV-to-oral switch therapy: Azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest 2002; 122 (4) :1271–1279.
   PubMed Web of Science ®Google Scholar
• Rapp RP. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: Enhanced tissue activity and minimal drug interactions. Ann Pharmacother 1998; 32 (7-8): 785–793.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Danziger LH, Gotfried MH. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 2003; 47 (8): 2450–2457.
   PubMed Web of Science ®Google Scholar
• Luke DR, Foulds G, Cohen SF, Levy B. Safety, tolera-tion, and pharmacokinetics of intravenous azithromycin. Antimicrob Agents Chemother 1996; 40 (11): 2577–2581.
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumo-nia. N Engl J Med 1997; 336 (4): 243–250.
   PubMed Web of Science ®Google Scholar
• Woodhead MA. Community-acquired pneumonia guide-lines an international comparison: A view from Europe. Chest 1998; 113 (Suppl. 3): 183-187.
   Google Scholar
• Tice AD. Community-acquired pneumonia: Recent insights into an old disease. Infect Med 2003; 20 (7): 352–356.
   Google Scholar
• Moran GJ. New directions in antiinfective therapy for community-acquired pneumonia in the emergency depart-ment. Pharmacotherapy 2001; 21 (7): 95–99.
   Web of Science ®Google Scholar
• Garey KW, Amsden GW. Intravenous azithromycin. Ann Pharmacother 1999; 33 (2): 218–228.
   PubMed Web of Science ®Google Scholar
• Luke DR, Foulds G. Toleration of intravenous azithromycin. Ann Pharmacother 1997; 31 (9): 965–969.
   PubMed Web of Science ®Google Scholar
• Plouffe J, Fields B, Nicolle L, Herbert M, Sherman B, Inverso J. Azithromycin (I.V./P0) in community-acquired pneumonia caused by Legionella pneumophila. 37th Annual Meeting of the Infectious Diseases Society of America. Philadelphia, 1999. Abstract.
   Google Scholar
• Zimmermann T, Laufen H, Riedel KD, Treadway G, Wildfeuer A. Comparative tolerability of IV azithromycin, clar-ithromycin and erythromycin in healthy volunteers. Results of a double-blind, double-dummy, four-way crossover study. Clin Drug Invest 2001; 21 (8): 527–536.
   Web of Science ®Google Scholar